Amplitude Venture Capital — 2023 Investments
2 investments dated 2023 · listed companies and verified rows first · show all
Radiant Biotherapeutics develops a platform of therapeutic molecules called Multabodies that engage multiple disease targets simultaneously within a single engineered protein to treat cancer and infectious diseases.
BiotechMedical Devices
Arthur Fratamico(Executive Officer, Promoter)Deborah Geraghty, Ph.D.(President and Chief Executive Officer)
Co-investorsFACIT (Fight Against Cancer Innovation Trust)Toronto Innovation Acceleration PartnersBill & Melinda Gates Foundation
Reverb Therapeutics develops immunotherapies built on its Amplify•R platform, which modulates the body's natural immune system using targeted molecules such as IL-15-directed compounds.
BiotechHealthtech
Co-investorsInBC Investment Corp.Thin Air LabsKdT Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.